id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-339122-7vvqtk84	Deb, Chaarushena	Covid-19, Single-Sourced Diagnostic Tests, and Innovation Policy	2020-07-07		.txt	text/plain	3117	167	49	16 An appropriate model for diagnostic testing development, including innovation incentives, should go beyond simply discouraging test monopolies and promoting confirmatory testing, by also allowing for low R&D costs for test development and yielding fast delivery of high quality tests-preventing the errors highlighted in the Covid-19 testing response from occurring in both emergency and non-emergency situations. And thus any sort of incentive model that relies on granting market exclusivity -such as the traditional patent system, FDA approval exclusivity, or trade secret protection -raises the same sorts of issues, if on a smaller scale, as those grimly demonstrated by the failure of U.S. SARS-CoV-2 testing at the onset of the Covid-19 pandemic, which ultimately resulted in the loss of many lives. But for diagnostic tests which rely on confirmatory testing, innovative improvements, and robust access to supply, single-sourcing creates a host of serious problems.	./cache/cord-339122-7vvqtk84.txt	./txt/cord-339122-7vvqtk84.txt